MA28335A1 - Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes - Google Patents

Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Info

Publication number
MA28335A1
MA28335A1 MA29206A MA29206A MA28335A1 MA 28335 A1 MA28335 A1 MA 28335A1 MA 29206 A MA29206 A MA 29206A MA 29206 A MA29206 A MA 29206A MA 28335 A1 MA28335 A1 MA 28335A1
Authority
MA
Morocco
Prior art keywords
agonists
vpac2
receptor
hypophysic
pacap
Prior art date
Application number
MA29206A
Other languages
English (en)
Inventor
Kevin Clairmont
Kevin J Lumb
Thomas Buckholz
Arthur I Salhanick
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28335A1 publication Critical patent/MA28335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

La présente invention fournit de nouveaux peptides qui agissent in vivo comme des agonistes du récepteur VPAC2. Il a été montré que ces polypeptides sécrétagogues de l'insuline abaissent la glycémie in vivo après une provocation par le glucose. Les polypeptides de la présente invention sont par ailleurs stables dans une formulation et ont des demi-vies prolongées. Les peptides de la présente invention offrent un traitement aux patients présentant une sécrétion d'insuline endogène réduite, par exemple les diabétiques de type 2. L'invention concerne en outre un procédé de traitement d'une maladie métabolique chez un mammifère comprenant l'administration d'une quantité efficace du point de vue thérapeutique desdits peptides audit mammifère.
MA29206A 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes MA28335A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
MA28335A1 true MA28335A1 (fr) 2006-12-01

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29206A MA28335A1 (fr) 2004-01-27 2006-07-24 Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes

Country Status (13)

Country Link
US (1) US20090143283A1 (fr)
EP (1) EP1713493A4 (fr)
JP (1) JP2007519739A (fr)
KR (1) KR20070009554A (fr)
AU (1) AU2005208911A1 (fr)
BR (1) BRPI0507177A (fr)
CA (1) CA2554475A1 (fr)
EC (1) ECSP066793A (fr)
IL (1) IL176705A0 (fr)
MA (1) MA28335A1 (fr)
NO (1) NO20063801L (fr)
RU (1) RU2006130691A (fr)
WO (1) WO2005072385A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001639A (zh) * 2004-06-12 2007-07-18 拜尔药品公司 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
US20090280106A1 (en) * 2005-05-06 2009-11-12 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2007050651A1 (fr) * 2005-10-26 2007-05-03 Eli Lilly And Company Agonistes peptidiques sélectifs du récepteur vpac2
CA2797033C (fr) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Polypeptides tres actifs et procedes pour les preparer et les utiliser
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN108055848B (zh) 2015-04-16 2021-10-01 H.伦德贝克公司 抗pacap抗体及其用途
MX2018012470A (es) 2016-04-15 2019-07-01 Alder Biopharmaceuticals Inc Anticuerpos anti pacap humanizados y usos de ellos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
AU7726600A (en) * 1999-09-28 2001-04-30 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
AU2003219787A1 (en) * 2002-02-14 2003-09-04 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
EP1578358A2 (fr) * 2002-07-12 2005-09-28 Bayer Pharmaceuticals Corporation Agonistes (vpac2) du recepteur de peptide activant l'adenylate cyclase pituitaire (pacap) et leurs methodes pharmacologiques

Also Published As

Publication number Publication date
EP1713493A4 (fr) 2009-06-24
US20090143283A1 (en) 2009-06-04
EP1713493A2 (fr) 2006-10-25
CA2554475A1 (fr) 2005-08-11
RU2006130691A (ru) 2008-03-10
WO2005072385A3 (fr) 2006-06-08
KR20070009554A (ko) 2007-01-18
IL176705A0 (en) 2006-10-31
AU2005208911A1 (en) 2005-08-11
BRPI0507177A (pt) 2007-06-26
ECSP066793A (fr) 2006-11-16
JP2007519739A (ja) 2007-07-19
NO20063801L (no) 2006-10-26
WO2005072385A2 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
MA28335A1 (fr) Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes
Henning et al. Vasoactive intestinal peptide: cardiovascular effects
Drucker Minireview: the glucagon-like peptides
Brown et al. Brain peptide regulation of adrenal epinephrine secretion
Larsen et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
Dogrukol-Ak et al. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects
Aronoff et al. Glucose metabolism and regulation: beyond insulin and glucagon
Bratusch-Marrain et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
DE60016393T2 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
Ludvik et al. Amylin: history and overview
Jensen et al. C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin
Boey et al. The role of peptide YY in regulating glucose homeostasis
CN103356996A (zh) Glp-1用于制备治疗急性冠脉综合征的药物的用途
Ahlborg et al. Metabolic and vascular effects of circulating endothelin-1 during moderately heavy prolonged exercise
WO2007065226A1 (fr) Fragments de vip et méthodes d'utilisation
CN106279400A (zh) P8降糖肽的设计及其用途
BR0312621A (pt) Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap)
CN1487952A (zh) 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
Uehlinger et al. Pressure dependence of atrial natriuretic peptide during norepinephrine infusion in humans.
Bray Food intake, sympathetic activity, and adrenal steroids
Plamboeck et al. The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1
Yokota et al. PACAP stimulates glucose output from the perfused rat liver
Wang et al. Cardiovascular actions of python bradykinin and substance P in the anesthetized python, Python regius
Antoniou et al. Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats
Patil et al. Role of insulin in management of type 2 diabetes mellitus